EDSA

Edesa Biotech, Inc. is a clinical-stage biopharmaceutical company developing ways to treat inflammatory and immune-related diseases. The Company’s clinical pipeline is focused on two therapeutic areas: medical dermatology and respiratory. In medical dermatology, the Company is developing EB06, an anti-CXCL10 monoclonal antibody candidate, as a therapy for vitiligo, a common autoimmune disorder that causes skin to lose its color in patches. Its medical dermatology assets also include EB01 (1.0% daniluromer cream), a Phase III-ready asset developed for use as a potential therapy for moderate-to-severe chronic allergic contact dermatitis (ACD), a common occupational skin condition. The Company’s advanced respiratory drug candidate is EB05 (paridiprubart), which is being evaluated in a United States government-funded platform study as a treatment for acute respiratory distress syndrome.

Wall Street analysts forecast EDSA stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for EDSA is 5.00 USD with a low forecast of 5.00 USD and a high forecast of 5.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

Edesa Biotech Inc revenue for the last quarter amounts to 0.00 USD, decreased % YoY.

Edesa Biotech Inc. EPS for the last quarter amounts to USD, decreased -100.00 % YoY.

Edesa Biotech Inc (EDSA) has 16 emplpoyees as of December 15 2025.

Today EDSA has the market capitalization of 12.77M USD.